Prescription drug · ANDA
Fulvestrant NDC 55150-394
Fulvestrant 50 mg/mL · Injection · Intravenous · Eugia US LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55150-394-02 | 55150039402 | 2 SYRINGE in 1 CARTON (55150-394-02) / 5 mL in 1 SYRINGEMarketed from Jun 30, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fulvestrant
- Generic name (nonproprietary)
- fulvestrant
- Active ingredients
- Fulvestrant — 50 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Eugia US LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215169
- Marketing start
- Listing expires
- Other FDA classes
- Estrogen Receptor Antagonists (Mechanism)Selective Estrogen Receptor Modulators (Mechanism)
- Identifiers
- Product ID 55150-394_01fb9018-5093-40e6-bfea-83dee3a5ffc0SPL ID 01fb9018-5093-40e6-bfea-83dee3a5ffc0SPL set ID 80b6dfe6-449d-4e2f-af90-bfbf9b04163bRxCUI 727762UNII 22X328QOC4UPC 0355150394012, 0355150394029
- Pharmacologic class
- Estrogen Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N455150039402followed by a unit qualifier and the quantityPackage 55150-0394-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metasta…
Excerpt only. Read the full label for complete information.